🔹 Revenue: $667M vs. $344M est. 🟢
🔹 EPS: $2.93 vs. $0.71 est. 🟢
Guidance:
🔹 FY25 Revenue: $975M–$1.025B (Est. $724M) 🟢
🔹 FY25 R&D + SG&A: $475M–$525M (Reiterated)
🔹 No guidance yet for Sanofi royalties/supply sales
Highlights:
🔸 FDA feedback suggests COVID-19 BLA approvable upon PMC alignment
🔸 $175M milestone from Sanofi triggered by BLA approval
🔸 SHIELD-Utah study: ~39% fewer side effects vs. mRNA vaccine
🔸 Expanded partnership with Takeda; $20M upfront + milestones
🔸 Raised FY25 revenue framework from $300–$350M to $975M–$1.025B
🔸 $519M net income in Q1; $603M recognized from terminated APAs